A protease variant and its application

By mutation of the amino acid site of Bacillus amylase protease, a protease variant with high ligase activity and low hydrolase activity was prepared, and the peptide combination of terpope peptides was combined, which solved the process in the prior art The problem of difficulty and low purity control has achieved efficient and low-cost tyrepo peptide synthesis, which is suitable for industrial production.

CN118685386BActive Publication Date: 2024-12-06GUANGDONG YITE BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411146979.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-12-06
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The prior art is difficult to control the process, low purity, and many impurities when synthesizing terpope peptides, especially the steric hindrance problems and hydrolysis side reactions caused by the content of hydrophobic amino acids, which affects the yield of the product and the applicability of industrial production.

Method used

Using protease variants derived from Bacillus amyloligosiliates, the ligase activity is improved and the hydrolase activity is reduced by mutation of specific amino acid sites. It is used to catalyze the coupling of peptides into terpopeptide and bind to solid phase Synthesis and biological expression methods simplify processes and reduce costs.

Benefits of technology

It has achieved high purity (over 99%) tyrepo peptide synthesis, which reduces impurity generation and hydrolysis side reactions, simplifies the process flow, is suitable for industrial production, and improves product yield and process stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118685386B_ABST
    Figure CN118685386B_ABST
Patent Text Reader

Abstract

The present disclosure provides a protease variant and its application. The protease variant disclosed in the present disclosure can catalyze the coupling of (a) a peptide C-terminal (thio) ester with (b) a peptide nucleophile having an N-terminal unprotected amine to synthesize tirpotide, and purify to obtain tirpotide refined peptide. The method provided in the present disclosure catalyzes the synthesis of tirpotide with a higher synthetic hydrolysis ratio, and there are few by-products in the reaction. The obtained tirpotide has high purity, simple process and easy control, low comprehensive cost, greatly reduces the generation of synthetic waste liquid, and is very suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the technical field of polypeptide synthesis, and in particular to a variant of protease derived from Bacillus amyloliquefaciens, and use of the variant in catalytic peptide coupling and synthesis of telpotide. Background Art

[0002] Tipoitide is a novel dual receptor agonist of glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It was approved by the US FDA in May 2022 as an adjunct therapy to diet and exercise to improve blood sugar control in adults with type 2 diabetes. In addition to its significant efficacy in treating type 2 diabetes and obesity, Tipoitide also shows certain therapeutic potential for non-alcoholic steatohepatitis.

[0003] Telpotide is composed of 17 amino acids with a total of 39 amino acids (including 37 coded amino acids and 2 non-coded amino acids), containing a C 20 Fatty diacids are connected to the lysine residues of the side chain through dimers of glutamic acid and 2-(2-(2-aminoethoxy)ethoxy)acetic acid. It has been reported that a solid phase synthesis / liquid phase synthesis combined strategy is used to synthesize telpotide, where four fragments of 1-14AA, 15-21AA, 22-29 AA, and 30-39 AA are first solid-phase synthesized separately, and then coupled by liquid phase synthesis to obtain crude telpotide peptide.

[0004] CN115991742A uses a solid phase synthesis method to connect the fragments. Although the liquid phase connection method is eliminated, the process control is difficult when coupling the fragments, the process is complicated, and the problem of low purity of the crude peptide cannot be avoided.

[0005] CN118005767A adopts a two-fragment method to prepare telpotide, firstly preparing fully protected fragment peptide 19-39, then preparing fully protected fragment peptide 1-18, and coupling the two to obtain fully protected telpotide.

[0006] CN117106055A first synthesizes the main chain peptide of telpotide from C-terminus to N-terminus by solid phase method, then removes the side chain protecting group R1 at the K20 site and sequentially couples each site of the side chain to obtain the crude telpotide peptide.

[0007] The longer the peptide chain is in solid phase synthesis, the more small impurities are produced in the middle. Telpotide has more hydrophobic amino acids, which produce greater steric hindrance during step-by-step coupling, resulting in difficulty in subsequent amino acid coupling, especially the four amino acids Phe22, Val23, Trp25, and Leu26, which affects the difficulty of purification and yield.

[0008] The main drawback of polycondensation of chemically side-chain protected oligopeptide fragments is that racemization can occur when the C-terminal amino acid residue of the acyl donor is activated. In contrast, enzyme-catalyzed peptide coupling is completely free of racemization and has no side reactions at the side chain functional groups. The use of enzyme-mediated peptide splicing is a promising strategy, which catalyzes the connection between peptide ester (acyl donor) and peptide amine (acyl acceptor) segments. Hydrolytic side reactions may occur when engineered proteases are used, including hydrolysis of the ester part of the acyl donor and very slow hydrolysis of the final product. Therefore, these side reactions must be minimized in order to maximize product yield.

[0009] Because it contains two non-coding amino acids, the difficulty of biosynthesis of telopoietin increases, and the method of synthesizing telopoietin by enzyme-mediated peptide splicing has not been reported. Therefore, a synthesis method with low production cost, few impurities, low purification difficulty, simple process and suitable for industrial production is urgently needed. Summary of the invention

[0010] In order to solve at least one of the above problems, the present disclosure provides a semi-synthetic method of telpotide. The method provided by the present disclosure can reduce the difficulty of amino acid coupling, reduce the hydrolysis side reaction and purification difficulty, and improve the product yield.

[0011] According to one aspect of the present disclosure, a protease variant is provided, which has improved ligase activity and has an amino acid mutation at one or more of positions 24, 50, 109, 118, 156, 166, 206, 218, 221, 222, 225 and 237.

[0012] In some embodiments, the protease variants of the present disclosure are capable of catalyzing the coupling (i.e., ligation reaction) of a peptide C-terminal (thio) ester with a peptide nucleophile having an N-terminal unprotected amine. Compared to a wild-type protease having an amino acid sequence as shown in SEQ ID NO: 3 or a protease variant having an amino acid sequence as shown in SEQ ID NO: 6, the protease variants provided by the present disclosure have increased ligase activity, and / or decreased hydrolase activity.

[0013] In some embodiments, the protease variant has one or more of the following mutations: S24N, M50F, N109S, N118S, E156S, G166H, Q206C, N218S, S221C, M222A, P225A, and K237R.

[0014] In some embodiments, the protease variant may also include a deletion of amino acids 75 to 83 (Δ75-83).

[0015] In some embodiments, the protease variant may also include a mutation at amino acid position 76.

[0016] In some embodiments, the protease variant may further include mutation N76D.

[0017] In some embodiments, the protease variant may further include a mutation at amino acid position 213.

[0018] In some embodiments, the protease variant may further include mutation K213R.

[0019] In some embodiments, the protease variant has any one or more amino acid mutations or deletions in S24N, M50F, Δ75-83, N109S, N118S, E156S, G166H, Q206C, N218S, S221C, M222A, P225A and K237R. In some embodiments, the protease variant has an amino acid sequence as shown in SEQ ID NO: 4, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.

[0020] In some embodiments, the protease variant has any one or more amino acid mutations of S24N, M50F, N76D, N109S, N118S, E156S, G166H, Q206C, K213R, N218S, S221C, M222A, P225A and K237R. In some embodiments, the protease variant has an amino acid sequence as shown in SEQ ID NO: 8, or an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity thereto.

[0021] The amino acid positions of the protease variants of the present disclosure are defined with reference to the amino acid sequence shown in SEQ ID NO:3.

[0022] According to yet another aspect of the present disclosure, a nucleic acid molecule is provided, which encodes the above-mentioned protease variant of the present disclosure.

[0023] According to another aspect of the present disclosure, an expression vector is provided, which comprises the above-mentioned nucleic acid molecule of the present disclosure.

[0024] In some embodiments, the expression vector includes a prokaryotic expression vector and a eukaryotic expression vector.

[0025] In some embodiments, the eukaryotic expression vector includes a yeast expression vector, a mammalian expression vector, an insect expression vector, and the like.

[0026] According to another aspect of the present disclosure, a host cell is provided, which comprises the above-mentioned nucleic acid molecule and / or expression vector of the present disclosure.

[0027] In some embodiments, the host cell is selected from a prokaryotic cell and a eukaryotic cell.

[0028] In some embodiments, the prokaryotic cell comprises a bacterial cell.

[0029] In some embodiments, the bacteria include Escherichia coli, Streptomyces, and Bacillus subtilis;

[0030] In some embodiments, the eukaryotic cells include yeast cells, mammalian cells, insect cells, etc.

[0031] In some embodiments, the mammal is selected from humans, monkeys, mice, rats, hamsters, goats, sheep, cows, pigs, dogs or cats.

[0032] In some embodiments, the mammalian cells include CHO cells, CHOK1 cells, 293 cells, Vero cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells.

[0033] In some embodiments, the bacterial cells include B. subtilis RIK1285 cells, WB600 cells, DH5α cells, BL21 cells, DH10Bac cells, XL10-Gold cells, TG1 cells, Stbl2 cells, BJ5183 cells, HB101 cells or Turbo cells.

[0034] According to yet another aspect of the present disclosure, there is provided a use of the protease variant in catalyzing the coupling of (a) a peptide C-terminal (thio)ester with (b) a peptide nucleophile having an N-terminal unprotected amine.

[0035] According to another aspect of the present disclosure, a method for synthesizing telpotide is provided, the method comprising the step of using the above-mentioned protease variant of the present disclosure to catalyze the coupling of (a) a peptide C-terminal (thio) ester with (b) a peptide nucleophile having an N-terminal unprotected amine.

[0036] In some embodiments, the coupling is performed in aqueous solution.

[0037] In some embodiments, the peptide nucleophile having an N-terminal unprotected amine comprises amino acids 17 to 39, 18 to 39, 19 to 39 and / or 20 to 39 of telpotide, and the 20th lysine is linked to a C20 -γ-Glu-(AEEA) 2 Sidechain.

[0038] In some embodiments, the peptide C-terminal (thio)ester includes amino acids 1 to 16, 1 to 17, 1 to 18 and / or 1 to 19 of telpotide.

[0039] In some embodiments, the N-terminal unprotected amine peptide nucleophile has the sequence H-Ile-Ala-Gln-Y-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser, where Y is lys[-C 20 -γ-Glu-(AEEA) 2 ].

[0040] In some embodiments, the peptide C-terminal (thio)ester has the sequence H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-(thio)ester.

[0041] In some embodiments, the coupling reaction is carried out at pH 7-10.

[0042] In some embodiments, the coupling is performed at pH 7, 8, 9, or 10.

[0043] In some embodiments, the molar ratio of the peptide C-terminal (thio)ester to the peptide nucleophile having an N-terminal unprotected amine is (1-100):(1-100).

[0044] In some embodiments, the molar ratio of the Bacillus amyloliquefaciens protease variant, the peptide C-terminal (thio)ester and the peptide nucleophile having an N-terminal unprotected amine is (1-10): (1-100): (1-100).

[0045] In some embodiments, the peptide nucleophile having an unprotected amine at the N-terminus is obtained by the following steps: 1) synthesizing a peptide segment comprising amino acids 17 to 39, 18 to 39, 19 to 39 and / or 20 to 39 of telpotide by biosynthesis; and, 2) attaching a C 20 -γ-Glu-(AEEA) 2 Sidechain.

[0046] In some embodiments, the step 1) synthesizes a peptide segment comprising amino acids 17 to 39 of tepoxetine (amino acid sequence Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser, SEQ ID NO: 14)

[0047] In some embodiments, the peptide C-terminal (thio)ester is synthesized by solid phase synthesis.

[0048] Beneficial effects:

[0049] The protease variants provided in the present disclosure have stronger ligase activity and weaker hydrolysis activity, good stability and high ligation efficiency.

[0050] The method disclosed herein adopts a semi-synthetic strategy, using a protease variant to catalyze the synthesis of telportin from a peptide segment. The reaction system has no racemization and few side reactions. Once the optimal conditions are reached, this synthetic system should be easy to mass produce peptides.

[0051] The telpotide prepared by the method disclosed in the present invention has high purity, which can reach more than 99%. The process is simple and easy to control, the overall cost is low, and the generation of synthetic waste liquid is greatly reduced, which is very suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 The purified recombinant polypeptide TR was tested by liquid phase analysis, and its purity was over 95%.

[0053] Figure 2 The figure shows the purified SDS-PAGE detection of the recombinant polypeptide ligase variant VA, wherein lane 1 is a standard protein marker and lane 2 is a recombinant polypeptide ligase variant VA.

[0054] Figure 3 The results of liquid phase detection of telpotide by reverse phase high performance liquid chromatography are shown.

[0055] Figure 4 The figure shows the liquid phase mass spectrometry result of Tipollination. DETAILED DESCRIPTION

[0056] The catalytic action of most proteases is reversible, and they can catalyze both protein hydrolysis and its ligation. However, these proteases are usually more inclined to proteolysis under physiological conditions. The inventors of the present disclosure have engineered and screened proteases derived from Bacillus amyloliquefaciens to obtain protease variants that are more inclined to peptide coupling.

[0057] Based on the protease variant provided by the present disclosure, the present disclosure proposes a semi-synthetic method of tirpotide, which divides tirpotide into two peptide segments, 1-16 peptide and 17-39 peptide, combines solid phase synthesis and biological expression to synthesize the first peptide fragment and the second peptide fragment, and then uses a polypeptide ligase to couple the first peptide fragment and the second peptide fragment to catalyze the synthesis of the peptide. The process is simple and easy to control, with low overall cost, greatly reducing the generation of synthetic waste liquid, and is very suitable for industrial production. Among them, the 17-39 peptide of tirpotide is obtained by biological expression and purification, and then side chain coupling is performed; the 1-16 peptide of tirpotide is synthesized by solid phase method and esterification modification is performed. Biological expression overcomes the steric hindrance problem caused by hydrophobic amino acids during chemical synthesis, reduces the difficulty of purification, and improves the product yield. Although there are strong hydrophobic groups on the lysine side chain of the amine segment of the peptide nucleophile, which is very spatially demanding, the peptide ligase variant used for catalytic synthesis greatly reduces the hydrolysis side reaction of the acyl donor ester part and the slow hydrolysis side reaction of the final product, greatly improves the product yield, makes the synthetic hydrolysis ratio higher, and realizes a single enzyme coupling reaction to synthesize telportopeptide with high yield.

[0058] To achieve the above-mentioned invention objectives, the present disclosure provides the following technical solutions: ① biological expression and purification of telpotide 17-39 peptides, followed by Lys20 side chain coupling and C-terminal modification; ② solid phase synthesis of telpotide 1-16 peptides, followed by -O-Cam-Leu esterification modification; ③ polypeptide ligase variant VA catalyzes the coupling reaction of 1-16 peptides (ester segment) and 17-39 peptides (nucleophilic reagent amine segment) to synthesize telpotide, which is then purified by reverse chromatography to obtain telpotide refined peptide.

[0059] In some embodiments, the present disclosure provides a method for synthesizing a peptide segment of telpotide 17-39, wherein the structure of the peptide segment of telpotide 17-39 is H-17Ile-18Ala-19Gln-20Lys[-C 20 -γ-Glu-(AEEA) 2 ]-21Ala-22Phe-23Val-

[0060] 24Gln-25Trp-26Leu-27Ile-28Ala-29Gly-30Gly-31Pro-32Ser-33Ser-34Gly-35Asn-36Pro-37Pro-38Pro-39Ser-NH 2 .

[0061] In some embodiments, the present disclosure provides a recombinant protein containing the tepote 17-39 peptide segment, whose structure is a tag protein-target polypeptide, and the amino acid sequence of the recombinant protein is as shown in SEQ ID NO.1, or is a conservative replacement sequence of the amino acid sequence shown in SEQ ID NO.1.

[0062] In some embodiments, the present disclosure also provides a nucleic acid molecule encoding the above-mentioned recombinant protein containing the telpotide 17-39 peptide segment.

[0063] In some embodiments, the present disclosure provides a vector comprising the above-mentioned nucleic acid molecule.

[0064] In some embodiments, the present disclosure provides a recombinant expression engineered bacterium that can express the above-mentioned recombinant protein.

[0065] In some embodiments, the present disclosure uses a self-cleaving tag protein Cytiva™ Protein Select™ resin affinity chromatography to purify a polypeptide of interest.

[0066] In some embodiments, in the above synthesis method, the side chain group C 20 -OtBu-Glu(OtBu)-AEEA-AEEA-OH forms an active ester, which is prepared into an alkaline solution and then coupled to 20Lys through processes such as distillation, acid adjustment, precipitation, and drying.

[0067] In some embodiments, ammonium chloride is used as an amino group donor to achieve C-terminal carboxyl transamination of the polypeptide of interest.

[0068] In some embodiments, the cleavage solution that can be used for the removal of side chain protecting groups includes TFA / TIS / H 2 O=95% / 2.5% / 2.5%.

[0069] In some embodiments, the present disclosure also provides a solid phase synthesis method for Cam ester-modified telpotide 1-16 peptide segment, wherein the structure of Cam ester-modified telpotide 1-16 peptide segment is: H-1Tyr-2Aib-3Glu-4Gly-5Thr-6Phe-7Thr-8Ser-9Asp-10Tyr-11Ser-12Ile-13Aib-14Leu-15Asp-16Lys-OCam-Leu-OH.

[0070] In some embodiments, the solid phase synthesis method comprises: using CTC resin as a solid phase carrier, and coupling the Cam esterification modification group to the CTC resin.

[0071] In some embodiments, the solid phase synthesis method comprises: preparing Fmoc-Leu-CTC resin by coupling reaction of Fmoc-Leu-OH with CTC resin, coupling with Fmoc-glycolic acid, and then sequentially coupling with Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Aib-OH, Fmoc-Ile-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-O H, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Aib-OH, and Boc-Tyr(tBu)-OH were coupled to obtain Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Ser(tBu)-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-OCam-Leu-CTC resin.

[0072] In some embodiments, in the solid phase synthesis method, the cleavage solution used for cleaving the protecting group is TFA / TIS / H 2 O=95% / 3.0% / 2.0%.

[0073] In some embodiments, the present disclosure provides a method of catalyzing the synthesis of telpotide by coupling a first peptide fragment and a second peptide fragment using the recombinant protease variant of the present disclosure.

[0074] In some embodiments, the present disclosure provides a recombinant protease variant VA, the protease variant VA comprising mutations at positions S24N, M50F, Δ75-83, N109S, N118S, E156S, G166H, Q206C, N218S, S221C, M222A, P225A, and K237R. In some embodiments, the protease variant has VA having an amino acid sequence as shown in SEQ ID NO: 4, or an amino acid sequence having one or more amino acid residues substituted, deleted or inserted compared to the amino acid sequence shown in SEQ ID NO: 4 and retaining ligase activity.

[0075] In some embodiments, the present disclosure provides a recombinant protease variant VA2, the recombinant protease variant VA2 comprising mutations of S24N, M50F, N76D, N109S, N118S, E156S, G166H, Q206C, K213R, N218S, S221C, M222A, P225A, K237R. In some embodiments, the recombinant protease variant VA2 has an amino acid sequence as shown in SEQ ID NO: 8, or an amino acid sequence having a substitution, deletion or insertion of one or more amino acid residues compared to the amino acid sequence shown in SEQ ID NO: 8 and retaining ligase activity.

[0076] In some embodiments, the present disclosure provides a recombinant expression engineered bacterium that can express the above-mentioned recombinant polypeptide ligase variant protease.

[0077] In some embodiments, the present disclosure provides the use of the above-mentioned recombinant protease variant of the present disclosure in catalyzing the coupling of Cam ester segment peptide fragment and nucleophile amine segment peptide fragment.

[0078] definition

[0079] Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly used in the field to which this disclosure belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0080] As used herein, the articles "a," "an," and "an" include plural referents unless the context clearly dictates otherwise.

[0081] The expression "about" as used herein is understood by one of ordinary skill in the art and varies within a certain range depending on the context in which it is used. If one of ordinary skill in the art is not aware of the use of the term based on the context in which it is used, "about" will mean up to plus or minus 10% of the specified value.

[0082] The term "mutation" as used herein includes amino acid substitution, deletion, insertion or any combination thereof. The "mutation" can generate amino acid mutations using genetic or chemical methods known in the art, including but not limited to methods such as site-directed mutagenesis, PCR, gene synthesis, etc. In some embodiments, the "mutation" of an amino acid can be used interchangeably with the "replacement", "displacement" or "substitution" of an amino acid, and can refer to the substitution of a conservative amino acid, wherein an amino acid residue is substituted with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced by another amino acid from the same side chain family, the substitution is considered conservative. In another aspect, a string of amino acids can be conservatively replaced with a structurally similar string that differs in the order and / or composition of the side chain family members.

[0083] The term "chemical synthesis" as used in this disclosure generally refers to artificially performing chemical reactions to obtain one or more products. Chemical synthesis can be performed by physical and chemical operations generally involving one or more reactions. Chemical synthesis may include a series of individual chemical reactions.

[0084] The term "biosynthesis" used in the present disclosure refers to synthesis (different from chemical synthesis) by means of biotechnological methods. For example, by loading the nucleic acid molecule encoding the target protein gene on a carrier, transfecting the host cell and expressing the target protein in the host cell. Exemplary host cells include prokaryotic cells and eukaryotic cells, such as Escherichia coli, Streptomyces, Bacillus subtilis, exemplarily including B.subtilis RIK1285 cells, WB600 cells, DH5α cells, BL21 cells, DH10Bac cells, XL10-Gold cells, TG1 cells, Stbl2 cells, BJ5183 cells, HB101 cells or Turbo cells. Cells can be cultivated using the standard methods of this area, and the target protein expressed can be harvested and purified from cell culture using the standard methods of this area.

[0085] The term "pharmaceutical composition" used in the present disclosure refers to any composition comprising at least one biologically active agent, such as the fusion protein. When used herein, the term "pharmaceutical composition" also refers to a composition comprising an active pharmaceutical ingredient to be delivered to a subject, such as to achieve a therapeutic, preventive, diagnostic, preventive or prognostic effect. The composition of the present disclosure can be administered as a food or health product, such as a nutritional supplement. Generally, the composition of the present disclosure is used to treat humans, but it can be used to treat animals, including monogastric mammals, such as poultry, pigs, cats, dogs, horses or rabbits. The composition of the present disclosure can be used to enhance the growth and performance of animals. If administered to an animal, oral gavage can be used.

[0086] The term "pharmaceutically acceptable carrier" used in the present disclosure refers to a substance that is suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), that is, a substance with a reasonable benefit / risk ratio. Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium lauryl sulfate), buffers, chelating agents, thickeners, pH regulators, transdermal enhancers, colorants, flavoring agents, stabilizers, antioxidants, preservatives, antibacterial agents, pyrogen-free water, etc.

[0087] As used herein, the term "nucleic acid molecule" refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.

[0088] As used herein, "percent homology", "% homology" or "% sequence identity" is used in the context of the present disclosure to describe the degree of similarity between two nucleotide sequences or two amino acid sequences, and has the same meaning as "percent identity". The percent homology of two sequences can be calculated as follows, after the two sequences are aligned, by dividing the number of positions where the residues are identical by the total length of the aligned sequences and multiplying by 100%. Methods and tools for aligning two amino acid sequences or nucleotide sequences are well known in the art, such as the BLAST suite provided on the NCBI website. As used herein, having "at least 85% sequence identity" to a sequence refers to having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence.

[0089] The sequence identity percentage can be calculated by the following process: determine the number of positions where the same amino acid residue or nucleic acid base occurs in both sequences to obtain the number of matching positions, divide the number of matching positions by the total number of positions in the comparison window, and multiply the result by 100 to obtain the sequence identity percentage. The comparison of sequences and the determination of the sequence identity percentage between the two sequences can be completed using software that is easy to use and download online. Suitable software programs are available from various sources for the comparison of protein and nucleotide sequences. A suitable program for determining the sequence identity percentage is bl2seq, which is part of the BLAST program suite available from the BLAST website (blast.ncbi.nlm.nih.gov) of the National Center for Biotechnology Information of the U.S. government. Bl2seq uses BLASTN or BLASTP algorithms to compare between two sequences. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk / Tools / psa.

[0090] The term "expression vector" as used herein refers to a DNA molecule that introduces a specific gene operably linked thereto into a target cell and directs expression. The expression vector includes vectors that are self-replicating nucleic acid structures and vectors that are incorporated into the genome of the host cell into which it has been introduced. The expression vector can perform transcription of a large amount of stable mRNA. Once the expression vector is in the target cell, the cellular transcription and / or translation machinery generates a ribonucleic acid molecule or protein encoded by the gene.

[0091] The term "host cell" as used herein is used interchangeably and refers to a cell into which an exogenous nucleic acid has been introduced, and also includes the offspring of such cells. Host cells include primary transformed cells and offspring derived therefrom. The nucleic acid of the offspring is completely identical to the parent cell, or not completely identical, and may contain mutations. Host cells include cultured cells, for example cultured mammalian cells, such as CHO cells, 293 cells, Vero cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells and plant cells. Host cells of the present disclosure also include cells contained in transgenic animals, transgenic plants or cultured plants or animal tissues.

[0092] The term "protecting group" as used herein includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to: formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as tert-butyloxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), etc. The term "hydroxy protecting group" refers to a protecting group suitable for preventing side reactions of the hydroxyl group. Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and tert-butyl; acyl groups such as alkanoyl (e.g., acetyl); arylmethyl groups such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), and the like.

[0093] The pharmaceutical composition can be in any dosage form, for example, including but not limited to tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, injections, sprays, aerosols, powder sprays, lotions, liniments, ointments, plasters, pastes, patches, eye drops, nasal drops, suppositories, etc.

[0094] The pharmaceutical composition of the present disclosure can be administered in a pharmaceutically effective amount. "Pharmaceutically effective amount" means that the amount used is sufficient to treat the disease, with a reasonable benefit / risk ratio applicable to any medical treatment. The effective dosage level of the composition can be determined based on the type of subject, the severity of the disease, the age and gender of the subject, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration, the excretion rate, the treatment time, the drug used in combination with the composition, and other known factors in the medical field. The pharmaceutical composition of the present disclosure can be used alone or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. The composition can be administered in one or more dosage forms.

[0095] As used herein, the term "treating" a disease in a subject or "treating" a subject having or suspected of having a disease refers to administering a drug therapy, such as administering one or more pharmaceutical agents, to a subject, thereby reducing or preventing worsening of at least one symptom of the disease. Thus, in some embodiments, "treating" refers, inter alia, to delaying progression, accelerating remission, inducing remission, increasing remission, accelerating recovery, increasing the efficacy of alternative therapies, or reducing resistance to alternative therapies, or a combination thereof.

[0096] As used herein, the terms "preventing" and "preventing" are art-recognized and well-known in the art when used in connection with a condition such as a local recurrence, and include administration of a composition that reduces the occurrence or delays the onset of symptoms of a medical condition in a subject relative to a subject not receiving the composition.

[0097] The term "inclusion body" as used herein refers to an insoluble deposit of aggregated polypeptides in the cytoplasm or nucleus. In this article, the term mainly refers to inclusion bodies formed in the cytoplasm of prokaryotic cells and bacterial cells. The term can also refer to polypeptide aggregates in the periplasm of prokaryotic cells and bacterial cells or to polypeptide aggregates in the cytoplasm and / or nucleus of eukaryotic cells. The aggregated polypeptides contained in the inclusion bodies may be misfolded, partially misfolded, or may have a natural or near-natural fold. The insoluble form of the polypeptide in the inclusion body protects the polypeptide from being degraded by proteolytic enzymes in the host cell. Moreover, the formation of inclusion bodies can help to separate and purify certain polypeptides, which are otherwise difficult to purify or require many and / or expensive purification steps. Means and methods for identifying inclusion bodies and quantifying the formation of inclusion bodies are well known in the art. Non-limiting examples of such means and methods include inclusion body fractionation assays, phase contrast microscopy, other optical measurement techniques, particle size measurements, gel separation assays (e.g., SDS-PAGE), proteolytic digestion, and electron microscopy.

[0098] Examples and drawings are provided below to help understand the present disclosure. However, it should be understood that these examples and drawings are only used to illustrate the present disclosure, but do not constitute any limitation. The actual protection scope of the present disclosure is set forth in the claims. It should be noted that for those skilled in the art, several variations and improvements made on the basis of this invention conception all belong to the protection scope of the present disclosure. The reagents used without indicating the manufacturer are all conventional products that can be obtained commercially.

[0099] Example

[0100] All amino acids were purchased from Jier Biochemical (Shanghai) Co., Ltd. The amino acids are: Fmoc-Tyr(tBu)-OH, Fmoc-Aib-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH. All organic solvents and inorganic salts were purchased from Xilong Science Co., Ltd. CTC resin was purchased from Nanjing Peptide Biotechnology Co., Ltd. C 20 Fatty acid side chain C 20-OtBu-Glu(OtBu)-AEEA-AEEA-OH was purchased from Yujun Biotechnology Co., Ltd. The expression vector used was purchased from Hunan Fenghui Biotechnology Co., Ltd., restriction endonucleases were purchased from New England Biotechnology (Beijing) Co., Ltd., ligases were purchased from Biyuntian Biotechnology Co., Ltd., and bacterial culture medium raw materials were purchased from Beijing Solebow Technology Co., Ltd.

[0101] The correspondence between English abbreviations and Chinese names is shown in Table 1.

[0102] Table 1. Correspondence between English abbreviations and Chinese names

[0103]

[0104] Example 1: Biosynthesis of Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser (SEQ ID NO: 14) recombinant polypeptide (TR1)

[0105] a. Obtaining the target gene: The recombinant protein encoding gene (SEQ ID NO: 2) containing the automatic cleavage tag and the recombinant polypeptide TR1 was codon-optimized and synthesized by Suzhou Genewise Biotechnology Co., Ltd. The amino acid sequence of the recombinant protein is shown in SEQ ID NO: 1. Using the synthetic gene SEQ ID NO: 2 as a template, PCR amplification was performed using primers P1 and P2. The primer sequences are as follows:

[0106] P1: aactttaagaaggagatataccATGGTGAAAATTGTGAGCCG (SEQ ID NO: 10)

[0107] P2: ctcgagtgcggccgcaagcttTTAGCTCGGTGGCGGGTTGC (SEQ IDNO: 11)

[0108] b. Construction of recombinant expression engineering bacteria: The expression vector pET28a (+) plasmid was double-digested with NcoI / HindIII. The digestion reaction system was 20μg pET28a (+) plasmid (50uL), 2uL NcoI, 2uL HindIII, 6uL10×cutsmart, and digested at 37℃ for 1 h to recover a linear vector fragment of about 5.2Kb. Then, seamless cloning was performed according to the system of vector pET28a (+) 50ng after double digestion with NcoI / HindIII, target fragment 50ng, and 2×seamless 4uL to obtain a recombinant expression vector named pET28a (+)-TR. pET28a (+)-TR was transformed into the host cell BL21 (DE3) to obtain the recombinant expression engineering bacteria named BL-TR.

[0109] c. Expression of recombinant protein: 5uL glycerol bacteria were inoculated into 5mL LB liquid medium containing 50μg / mL Kana, and cultured at 37℃, 220rpm for 16h. The ratio of bacteria liquid: medium = 1:100 (v:v) was inoculated into LB liquid medium containing 50μg / ml Kana, and cultured at 37℃, 220rpm until OD 600 The concentration of isopropylthiogalactoside (IPTG) was about 1, and the final concentration was 0.5 mM. The cells were induced at 30°C for 20 h. The cells were collected and ultrasonically disrupted to obtain inclusion bodies.

[0110] d. Purification of recombinant protein: The inclusion bodies were washed twice with inclusion body washing buffer, and inclusion body denaturation buffer was added at a ratio of 1:3 (m / v). The mixture was stirred at 25°C for 1 hour until the inclusion body solution became clear. The supernatant was collected and the protein concentration was determined to be 320 mg / mL. The protein was diluted and renatured with a final concentration of 5 mg / mL in the inclusion body renaturation buffer, and stirred at 25°C for 4 hours. After protein renaturation, the recombinant polypeptide was purified by affinity chromatography using Cytiva™ Protein Select™ resin purchased from Cytiva. After loading and balancing, when the CytivaProtein Select filler ligand and the tag were folded together, automatic cleavage occurred, and the polypeptide was cleaved and eluted from the tag by itself. There was no residual tag amino acid, and finally a 23aa TR1 recombinant polypeptide with a purity of more than 95% was obtained (see the test results). Figure 1 ). The required buffer is as follows:

[0111] Inclusion body washing buffer: 50mM PB, 0.1mM EDTA, pH7; inclusion body denaturation buffer: 8M urea, 50mMPB, 10mM DTT, pH7; inclusion body renaturation buffer: 0.5mM urea, 50mM PB, 0.3mM GSH, 1mM GSSG, pH7; chromatography buffer: 50mM PB, pH7.

[0112] Example 2: Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser recombinant polypeptide Lys side chain condensation and C-terminal carboxyl transamination

[0113]

[0114] a. Side chain synthesis: Purchase side chain C 20 -OtBu-Glu(OtBu)-AEEA-AEEA-OH (Yujun Biotechnology), the structural formula is as follows:

[0115] Weigh 100g (114.39mmol 1.0eq) of side chain and add it to a 2000mL round-bottom flask, add 800mL of dichloromethane (DCM) to dissolve and clarify, and cool to 0~10℃. Weigh 28.32g (137.27mmol 1.2eq) of DCC, dissolve and clarify with 100mL of dichloromethane, and drop it into the above reaction solution for 30~60min. After the addition is completed, continue the reaction for 10~30min. Weigh 15.80g (137.27 1.2eq) of HOSU, dissolve and clarify with 100mL of dichloromethane, and drop it into the above reaction solution for 30~60min. After the addition is completed, continue the reaction for 2.0~3.0 hours, take samples, and perform HPLC detection. The raw materials are basically reacted (the peak area of ​​HPLC detection is less than 2.0%). After the reaction is completed, the reaction solution is filtered, and the filtrate is concentrated in vacuo until there is substantially no droplets.

[0116] b. Side chain condensation: Add 226.75 g (99.47 mmol 1.0 eq) of the TR1 recombinant polypeptide obtained in Example 1 to 4535 mL (20.0 eq) of purified water and 4535 ml (20.0 eq) of tetrahydrofuran, and add 12.86 g (994.7 mmol 10.0 eq) of diisopropylethylamine, stir to dissolve and clarify, and control the temperature of the solution at 15-20°C. Add 1.0 L (9.0 eq) of tetrahydrofuran to dissolve and clarify the product obtained in step a, and titrate the solution in the above reaction solution, and control the titration time to 1.5-2.0 hours. After the titration is completed, continue the reaction for 30-60 minutes, take samples for detection, and after the reaction is complete (the raw material peak area accounts for less than 3.0%), concentrate the tetrahydrofuran. The remaining concentrated solution was added with 4535 mL of purified water, and the pH was adjusted to 8.30-8.35 with hydrochloric acid to precipitate the product. After precipitation, the product was allowed to stand for 3.0-5.0 hours, and the supernatant was removed. The obtained product was added with 2.26 L (10.0 Vol) of N,N-dimethylformamide (DMF) to dissolve into a suspension, and then precipitated into a white solid in 22.6 L (100.0 Vol) of methyl tert-butyl ether. The obtained product was continuously slurried with 2.26 L of dichloromethane twice to obtain a white solid for vacuum drying.

[0117] c. Convert the carboxyl group to the amino group: Add 31.36 g (10 mmol 1.0 eq) of white solid to acetonitrile / H 2 O=1:1100mL and add 1.06g sodium carbonate (10mmol 1.0eq) and stir to dissolve and clarify. Add 1.92g EDC.HCl (10mmol 1.0eq) under stirring and continue stirring and reacting for 30~60min, then add 1.07g ammonium chloride (20mmol 2.0eq) and continue stirring and reacting for 10.0~16.0 hours. After concentrating acetonitrile (ACN), adjust pH to 8.24~8.30 with hydrochloric acid to precipitate the product, remove the liquid, and obtain the product for freeze-drying.

[0118] d. Remove the side chain protecting group: add the lyophilized solid to the cutting solution TFA / TIS / H 2 O=95% / 2.5% / 2.5% (10 mL / g). Stir the reaction at 25-30 °C for 2.0 hours. Add the cutting solution into methyl tert-butyl ether (100 mL / g) to precipitate a white solid. Centrifuge the precipitate to obtain a white solid, which is washed four times with methyl tert-butyl ether and then dried under vacuum to obtain H-Ile-Ala-Gln-Lys[diacid-C 20 -γ-Glu-(AEEA) 2]-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser-NH 2 .

[0119] Example 3: Solid Phase Synthesis of H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH

[0120] H-Leu-CTC resin was prepared according to the following route:

[0121]

[0122] The details are as follows:

[0123] a. Preparation of Fmoc-glycolic acid: Weigh 132.16g (1000mmol 1.0eq) of compound 1, dissolve and clarify with 100ml of dichloromethane solvent, add 7.91g (100mmol 0.1eq) of pyridine, and then weigh 310.45g (1200mmol 1.2eq) of compound 2, dissolve and clarify with 32ml of dichloromethane, and then add dropwise to the reaction solution. The titration time is controlled at 15-30min. After the addition is completed, continue to stir and react for 2.0 hours, concentrate the reaction solution solvent to dryness, add an appropriate amount of sodium bicarbonate aqueous solution to the remaining material and stir, add ethyl acetate to extract after stirring, add anhydrous sodium sulfate to dry the organic layer filtrate, filter and concentrate the filtrate to dryness to obtain 282.2g of compound 3. Prepare 2.8 L of TFA / TIS / DCM = 90% / 3.0% / 7.0% cutting solution, add compound 3 to the cutting solution, stir and react at 20-25°C for 2.0-2.5 hours, add 28 L of methyl tert-butyl ether to the reaction solution to precipitate a white solid, wash it 4 times with an appropriate amount of methyl tert-butyl ether and dry it to obtain 214.8 g of Fmoc-glycolic acid.

[0124] b. Preparation of H-Leu-CTC resin: Weigh 30g of CTC resin (substitution degree is 0.8mmol / g) into a 2.0L solid phase synthesis reaction column, add 200mL DMF and stir to swell the resin for 30min. Weigh 25.42g of Fmoc-Leu-OH (72.0mmol3.0eq) and dissolve and clarify with 150mL DMF solvent, add 6.20g of N,N-diisopropylethylamine (DIEA) (48mmol 2.0eq), and react under stirring at room temperature for 7.0~9.0 hours. After the reaction liquid is pumped off, add 250mL of DMF to wash 4 times, add 20% piperidine / DMF 250mL to remove Fmoc 2 times, each time for 10min. Wash with DMF 6 times, each time 250mL, to obtain H-Leu-CTC resin.

[0125] c. Cam modification group coupling CTC resin: Weigh 14.32g (48mmol 2.0eq) of Fmoc-glycolic acid and 7.14g (52.8mmol 2.2eq) of 1-hydroxybenzotriazole (HOBT), add 200mL of DMF to dissolve and clarify, add 9.09g (72.0mmol 3.0eq) of N,N′-diisopropylcarbodiimide (DIC) to mix, add to H-Leu-CTC resin and stir for 2.0 hours, detect with ninhydrin, after the reaction, wash the peptide resin with DMF 4 times, after washing, add 20% piperidine / DMF to remove Fmoc 2 times, 10min each time. Wash with DMF 6 times, 250mL each time.

[0126] H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH was prepared as follows:

[0127]

[0128] The details are as follows:

[0129] d. Preparation of H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH: The resin obtained in step c is further reacted with Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Aib-OH, Fmoc-Ile-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Th The resin was obtained by coupling reaction of Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Aib-OH and Boc-Tyr(tBu)-OH to obtain Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Ser(tBu)-Ile-Aib-Leu-Asp(OtBu)-Lys(Boc)-OCam-Leu-CTC resin. The resin was washed with DCM for 6 times, dried and TFA / TIS / H 2 O=95% / 3.0% / 2.0% was added thereto in a volume of 10 vol, and the reaction was stirred at room temperature for 2.0 hours. After filtering, the filtrate was precipitated with 100 vol of methyl tert-butyl ether and dried to obtain H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH.

[0130] Example 4: Cloning, expression and purification of recombinant polypeptide ligase variant VA

[0131] The catalytic action of most proteases is reversible, and proteases can catalyze both protein hydrolysis and ligation, but are more inclined to protein hydrolysis under physiological conditions. Therefore, the inventors of the present disclosure attempted to engineer proteases, conducted experiments, and tested whether proteases that are more conducive to ligation could be obtained.

[0132] In this example, a protease (encoding gene Genebank ID: K02496.1) is used, the start codon is GTG, and the encoded amino acid sequence includes a signal peptide, a leader peptide, and a mature peptide. The mature peptide amino acid coding sequence is SEQ ID NO: 3, and the signal peptide and the leader peptide are cleaved when fully mature.

[0133] On this basis, the inventors screened a peptide synthetase variant VA (amino acid sequence as shown in SEQ ID NO: 4), which contains the following position mutations: S24N, M50F, Δ75-83, N109S, N118S, E156S, G166H, Q206C, N218S, S221C, M222A, P225A, K237R. A 6*His tag was added to the C-terminus of the protein for rapid and efficient purification.

[0134] a. Obtain the target gene: According to the wild-type coding gene Genebank ID: K02496.1 and the amino acid sequence information of SEQ ID NO: 4 of the peptide synthetase variant VA1, the sequence of the coding gene for the signal peptide, leader peptide, and mature peptide sequence is obtained as shown in SEQ ID NO: 5. The coding gene was codon optimized and synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. Using the synthetic gene SEQ ID NO: 5 as a template, primers P3 and P4 were used to PCR amplify the target fragment of about 1.2 kbp. The primer sequences are as follows:

[0135] P3:AGCAAAAGGAGAGGGACGCGTGTGAGAGGCAAAAAAGTATG (SEQ ID NO: 12)

[0136] P4:GACAAGCTTGAATTCGGATCCTTAATGATGGTGATGGTGATGTTGTG (SEQ ID NO: 13)

[0137] b. Construction of recombinant expression engineering bacteria: The expression vector pBE-S was double-digested with MluI / BamHI. The digestion reaction system was 20μg vector (50uL), 2uL MluI, 2uL BamHI, 6uL10×cutsmart, and digested at 37 degrees for 1 hour to recover a linear vector fragment of about 6Kb. Then, seamless cloning was performed according to the system of 50ng of vector pBE-S after MluI / BamHI double digestion, 150ng of target fragment, and 2×seamless4uL to obtain a recombinant expression vector named pBES-VA. pBES-VA was transformed into the host cell B.subtilis RIK1285 to obtain a recombinant expression engineering bacteria named Bs-VA.

[0138] c. Expression of recombinant polypeptide ligase variants: 5uL glycerol bacteria were inoculated into 5ml LB liquid medium containing 50μg / mL Kana, and cultured at 37℃, 220rpm for 16h. The bacteria were inoculated into LB liquid medium with 50μg / mL Kana at a ratio of 1:100 (v:v), and cultured at 37℃, 220rpm for 24~48h. The fermentation supernatant was detected by SDS-PAGE electrophoresis.

[0139] d. Purification of recombinant peptide ligase variants: The fermentation supernatants were collected separately, and ammonium sulfate was added to 40%-50% saturation, and the precipitate was collected and precipitated with 20mM Tris, 300mM NaCl, 2mM CaCl 2 , pH 7 buffer, resuspended, filtered through a 0.45 μm filter membrane, loaded onto a well-equilibrated nickel column for recombinant protein purification, and the protein eluate was detected by SDS-PAGE (see Figure 2 ). The required mobile phase is as follows:

[0140] Equilibration solution: 20mM Tris, 300mM NaCl, 10mM imidazole, pH7; washing solution: 20mM Tris, 300mM NaCl, 30mM imidazole, pH7; elution solution: 20mM Tris, 300mM NaCl, 250mM imidazole, pH7.

[0141] Example 5: Application of polypeptide ligase variant VA in the synthesis of telportin

[0142] The peptide synthesis was catalyzed by coupling the first peptide fragment and the second peptide fragment using the polypeptide ligase variant VA, respectively, wherein the first fragment was a 16-mer terminal Cam ester segment (obtained from Example 3) and the second fragment was a 23-mer peptide nucleophile amine segment with an N-terminal unprotected amine (obtained from Example 2).

[0143] The ligation reaction was carried out at room temperature. 18.77g of the first fragment was dissolved in 5L of 200mM Tricine, 2M guanidine hydrochloride, pH 8 buffer, and 10.09g of the second fragment was dissolved in 5mL of 200mM Tricine, 2M guanidine hydrochloride, pH 8 buffer. The Cam ester segment and amine segment solutions were mixed and then 200mL of 100 mg / mL TCEP buffer was added. The final concentrations of the first and second segments in the mixture were 0.5 mM and 0.6 mM, respectively. 10L of 200mM Tricine, pH 8 buffer was added, and then the polypeptide ligase variant VA was added. The final concentration of the polypeptide ligase variant VA was 10μM. The ligation reaction lasted for 3 hours and the pH was kept constant at 8. After the reaction, 40 L of 3:1 acetonitrile: water stop solution was added to the ligation reaction solution. The solution was purified by reversed-phase high-performance liquid chromatography using a C18 column. The purity was more than 99%. The mobile phase gradient was 15-30% acetonitrile / water + 0.05% trifluoroacetic acid (TFA). The liquid phase detection results of reversed-phase high-performance liquid chromatography are shown in Figure 3 The mass spectrometry results of the purified product are shown in Figure 4 .

[0144] During the ligation reaction, 10uL of the sample was taken every 30 minutes, and 500uL of 3:1 acetonitrile:water stop solution was added for LC-MS analysis. After 3h of reaction, the Cam ester was completely consumed, and the ligation product was H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys[diacid-C 20 -γ-Glu-(AEEA) 2 ]-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser-NH 2 The area of ​​the hydrolyzed Cam ester H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OH is 95%, and the area of ​​the hydrolyzed Cam ester H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OH is 5%. Although there are strong hydrophobic groups on the lysine side chain of the peptide nucleophile amine segment, which is very demanding spatially, it still has a high synthesis / hydrolysis ratio in this reaction, so that a single enzyme coupling reaction can synthesize tepote in high yield.

[0145] Example 6: Comparison of catalytic coupling activities of different protease variants

[0146] As mentioned above, the catalytic action of most proteases is reversible. Proteases can catalyze both protein hydrolysis and ligation, but under physiological conditions they tend to hydrolyze protein more strongly.

[0147] Here we expressed the peptide ligase variant VA1, which was first recombinantly expressed by the Wells team (Chang T K et al., Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(26): 12544-12548), and can significantly increase the ligase activity (increase by 1 order of magnitude) and reduce the hydrolase activity (reduced by 2 orders of magnitude). The ligase variant VA1 contains the following 7 position mutations: M50F, N76D, N109S, K213R, N218S, S221C, P225A, and the mature peptide amino acid sequence is shown in SEQ ID NO: 6. A 6×His tag was added to the C-terminus of the protein for rapid and efficient purification, and the coding gene containing the signal peptide, leader peptide, and mature peptide is shown in SEQ ID NO: 7.

[0148] Based on the polypeptide ligase variant VA1, 7 additional position mutations were introduced into the mature peptide region: S24N, N118S, E156S, G166H, Q206C, M222A, K237R to obtain variant VA2. Variant VA2 contains the following 14 position mutations: S24N, M50F, N76D, N109S, N118S, E156S, G166H, Q206C, K213R, N218S, S221C, M222A, P225A, K237R, and the amino acid sequence of the mature peptide is shown in SEQ ID NO: 8. A 6×His tag was added to the C-terminus of the protein for rapid and efficient purification, and the coding gene containing the signal peptide, leader peptide, and mature peptide is shown in SEQ ID NO: 9.

[0149] According to the method of Example 4, recombinant expression vectors pBES-VA1 and pBES-VA2 were constructed, and then transformed into host cells B. subtilis RIK1285 to obtain recombinant expression engineering bacteria Bs-VA1 and Bs-VA2. The recombinant expression engineering bacteria Bs-VA1 and Bs-VA2 were fermented to express and purify polypeptide ligase variants VA1 and VA2.

[0150] According to the method of Example 5, polypeptide ligase variants VA, VA1, and VA2 were used to catalyze the coupling of the first peptide fragment and the second peptide fragment of telpoxetine, respectively, and samples were taken every 30 minutes. The coupling time, connection product, and hydrolysis product are detailed in Table 2. The coupling reaction time of polypeptide ligase variant VA1 increased, the proportion of hydrolysis reaction was high, the ratio of connection product / hydrolysis product was small, and the efficiency was low; polypeptide ligase variant VA2 greatly reduced the occurrence of hydrolysis reaction and increased the ratio of connection product / hydrolysis product.

[0151] Table 2 Coupling reactions catalyzed by peptide ligase variants

[0152]

[0153] The technical solution of the present disclosure is not limited to the above-mentioned specific embodiments, and all technical variations made according to the technical solution of the present disclosure fall within the protection scope of the present disclosure.

Claims

1. A protease variant, characterized in that The protease variant has the amino acid sequence shown in SEQ ID NO:

4.

2. A nucleic acid molecule encoding the protease variant of claim 1. An expression vector comprising the nucleic acid molecule according to claim 2 . A host cell comprising the nucleic acid molecule according to claim 2 and / or the expression vector according to claim 3.

5. Use of the protease variant of claim 1, the nucleic acid molecule of claim 2, the expression vector of claim 3 or the host cell of claim 4 in catalyzing the coupling of (a) a Cam ester with (b) a peptide nucleophile having an N-terminal unprotected amine; The Cam ester has the sequence H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH; The peptide nucleophile with an N-terminal unprotected amine has the sequence H-Ile-Ala-Gln-Y-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser, wherein Y is Lys[-C 20 -γ-Glu-(AEEA)2].

6. A method for synthesizing telpotide, comprising the step of using the protease variant of claim 1 to catalyze the coupling of the following substances: (a) a Cam ester having the sequence H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-OCam-Leu-OH; and (b) a peptide nucleophile with an N-terminal unprotected amine having the sequence H-Ile-Ala-Gln-Y-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser, wherein Y is Lys[-C 20 -γ-Glu-(AEEA)2].

7. The synthesis method according to claim 6, characterized in that The coupling is carried out in aqueous solution.

8. The synthesis method according to claim 6, characterized in that The peptide nucleophile having an N-terminal unprotected amine is obtained by the following steps: Biosynthetically synthesizing Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Asn-Pro-Pro-Pro-Ser; and Attach C to Lys residues 20 -γ-Glu-(AEEA)2 side chain.

9. The synthesis method according to claim 6, characterized in that: The Cam esters were synthesized by solid phase synthesis.

Citation Information

Patent Citations

  • Synthesis method of tilpotide

    CN117106055A

  • Peptide fragment condensation and cyclisation using a subtilisin variant with improved synthesis over hydrolysis ratio

    CN107002110A

  • Subtilisin variants and uses thereof

    CN117098843A